---
document_datetime: 2025-09-17 16:30:26
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/jemperli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: jemperli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3997858
conversion_datetime: 2025-12-21 21:05:24.633284
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## JEMPERLI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number      | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|-------------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Marketing Authorisation | - Transfer of a marketing authorisation - | 01/09/2025                          | 15/09/2025                                  | SmPC,                            |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Transfer - H / EMA/T/0000292052          | transfer of marketing authorisation from GlaxoSmithKline (Ireland) Limited to GlaxoSmithKline Trading Services Limited                                                                                                                                                                                                                                                                                                      |            |            | Labelling and PL   |                                                                                                                                                                                        |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000287894 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                                         | 11/08/2025 | N/A        |                    |                                                                                                                                                                                        |
| Variation type IB / EMA/VR/0000264716    | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted | 16/06/2025 | N/A        |                    |                                                                                                                                                                                        |
| Variation type IB / EMA/VR/0000263951    | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                                                               | 06/06/2025 | N/A        |                    |                                                                                                                                                                                        |
| Variation type II / EMA/VR/0000256521    | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7                                                                                                                                                                                                                                                                                                                                          | 05/06/2025 | 15/09/2025 | Annex II and PL    | The Annex II has been updated to add the new manufacturer responsible for batch release: GlaxoSmithKline Manufacturing S.p.A Strada Provinciale Asolana, 90, 43056 San Polo di Torrile |

<div style=\"page-break-after: always\"></div>

|                                       | Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.3 Including batch control/testing for a biological/immunological product and any of the test methods performed at that site is a biological / immunological / immunochemical method - Accepted   |            |     | Parma, Italy   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| Variation type IB / EMA/VR/0000255440 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/04/2025 | N/A |                |
| Variation type IB / EMA/VR/0000248620 | This was an application for a group of variations. B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                              | 20/02/2025 | N/A |                |

<div style=\"page-break-after: always\"></div>

| B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted   |
|--------------------------------------------------------------|